MUC1 and adrenal cortex carcinoma: As the drug treatment in advanced/metastatic ACC patients that progressed after EDP-M is still an unmet clinical need, this study was mainly dedicated to the evaluation of Pg activity in ACC metastatic cell lines (MUC-1 and TVBF-7), and to study its effect on NCI-H295R cells, which represent the widely known experimental cell model of ACC.